Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK-01 (LY3295668) in Advanced Solid Tumors
NCT03092934Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of LY3295668 in small cell lung cancer (SCLC), breast cancer, triple-negative breast cancer (TNBC), head and neck cancer (HNC), solid tumor, sponsored by Eli Lilly and Company. Started May 2017; status: completed.
02
Drugs
LY3295668
03
Conditions
small cell lung cancer (SCLC)breast cancertriple-negative breast cancer (TNBC)head and neck cancer (HNC)solid tumor
Beyond the preview
Go deeper on NCT03092934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092934.